CellCentric
Last verified 2026-05-13. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $300.0Mattributed |
|---|---|
| Latest round | series-d+, $220.0M, 2026-05-06attributed |
| Founded | 2010 |
| Headquarters | Cambridge |
| Industry | bio |
| Stage | series-b+ |
| Website | cellcentric.com |
CellCentric develops inobrodib, a first-in-class oral small-molecule inhibitor of p300/CBP designed to treat multiple myeloma and other cancers by disrupting cancer cell growth. It targets patients who want effective treatments taken orally in community settings rather than hospitals. The oral approach expands access and reduces healthcare system burden versus complex existing therapies.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-05-06 | series-d+ | $220.0M | undisclosed |
Detected tech stack
Cloudflare, WordPress 6.9.4, Tagembed, Google Analytics, Google Tag Manager, Swiper, jQuery Migrate 3.4.1, Elementor 4.0.8, PHP, DoubleClick Floodlight, CookieYes 3.4.2, Python
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series D+, $220.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $300.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | cellcentric.com, read 2026-05-13 |
| Description | self-reported | cellcentric.com, read 2026-05-13 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.